

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Purepac Pharmaceutical Co.		10/26/2005	CORPORATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Bank of America, N.A., as Agent		
<b>Street Address:</b>	300 Galleria Parkway, Suite 800		
<b>City:</b>	Atlanta		
<b>State/Country:</b>	GEORGIA		
<b>Postal Code:</b>	30339		
<b>Entity Type:</b>	National Banking Association:		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	1801834	P	
<b>Registration Number:</b>	1785154	PUREPAC	
<b>Serial Number:</b>	78565691	PUREPAC	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(404)522-8409		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
<b>Phone:</b>	(404) 420-5527		
<b>Email:</b>	rbirdwell@phrd.com		
<b>Correspondent Name:</b>	Rhonda J. Birdwell, Paralegal		
<b>Address Line 1:</b>	285 Peachtree Center Avenue		
<b>Address Line 2:</b>	1500 Marquis Two Tower		
<b>Address Line 4:</b>	Atlanta, GEORGIA 30303		
<b>ATTORNEY DOCKET NUMBER:</b>	1809-41 ALPHARMA		
<b>NAME OF SUBMITTER:</b>	Bobbi Acord		

CH \$90.00 1801834

Signature:	/ba/
Date:	11/10/2005
<b>Total Attachments: 7</b> source=Trademark Notice 2#page1.tif source=Trademark Notice 2#page2.tif source=Trademark Notice 2#page3.tif source=Trademark Notice 2#page4.tif source=Trademark Notice 2#page5.tif source=Trademark Notice 2#page6.tif source=Trademark Notice 2#page7.tif	

**NOTICE OF  
GRANT OF SECURITY INTEREST  
IN  
TRADEMARKS  
("NOTICE")**

United States Patent and Trademark Office

Ladies and Gentlemen:

Please be advised that pursuant to that certain Loan and Security Agreement dated October 26, 2005 (as amended and supplemented from time to time, the "Loan Agreement") by and among Alharma Inc., a Delaware corporation, Alharma Operating Corporation, a Delaware corporation, Alharma USPD Inc., a Maryland corporation, Alharma U.S. Inc., a Delaware corporation, G.F. Reilly Company, a Delaware corporation, Parmed Pharmaceuticals, Inc., a Delaware corporation, Alharma Euro Holdings Inc., a Delaware corporation, Alharma (Bermuda) Inc., a Delaware corporation, Alharma USHP Inc., a Delaware corporation, Alharma Animal Health Company, a Texas corporation, Mikjan Corporation, an Arkansas corporation, Alharma Holdings Inc., a Delaware corporation, Alharma Pharmaceuticals Inc., a Delaware corporation, Purepac Pharmaceutical Holdings, Inc., a Delaware corporation, Alharma Branded Products Division Inc., a Delaware corporation, Purepac Pharmaceutical Co., a Delaware corporation ("Purepac"), and Alharma Investment Inc., a Delaware corporation, the various financial institutions party thereto from time to time (collectively, "Lenders"), and Bank of America, N.A., a national banking association, as collateral and administrative agent for Lenders (together with its successors in such capacity, "Agent"), and that certain Trademark Security Agreement dated October 26, 2005 (as amended and supplemented from time to time, the "Trademark Security Agreement") by and between Purepac and Agent, Purepac has granted to Agent, for the benefit of itself and Lenders, a continuing security interest in, and continuing lien upon, the trademark and service mark registrations and applications listed on Exhibit A attached hereto together with the goodwill of the business connected therewith and symbolized thereby and all proceeds thereof (the "Trademark Collateral").

Purepac and Agent hereby acknowledge and agree that the security interest in and lien upon the Trademark Collateral may only be terminated in accordance with the terms of the Loan Agreement and the Trademark Security Agreement (the "Financing Agreements").

Notwithstanding anything contained in this Notice, in the event that any provisions of this Notice are deemed to conflict or be inconsistent with the Financing Agreements, the provisions of the Financing Agreements shall govern.

[Signatures on following page]

Very truly yours,

**PUREPAC PHARMACEUTICAL CO.**

By: 

Name: Frederick J. Lynch

Title: President & Chief Executive Officer

Acknowledged and Accepted:

**BANK OF AMERICA, N.A., as Agent**

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title \_\_\_\_\_

Very truly yours,

**PUREPAC PHARMACEUTICAL CO.**

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Acknowledged and Accepted:

**BANK OF AMERICA, N.A., as Agent**

By: 

Name: Johnson

Title: Vice President

STATE OF NEW JERSEY

§

§

COUNTY OF BERGEN

§

BEFORE ME, the undersigned authority, on this day personally appeared Frederick J. Lynch, President & Chief Executive Officer of Purepac Pharmaceutical Co., to me known to be the person whose name is subscribed to the foregoing instrument, and acknowledged to me that he executed the same for the purposes therein expressed, in the capacity therein stated, and as the act and deed of said corporation.

GIVEN UNDER MY HAND AND SEAL OF OFFICE on this 26<sup>th</sup> day of October, 2005.



Notary Public

My Commission Expires: May 19, 2007

PATRICIA D. JONES  
NOTARY PUBLIC OF NEW JERSEY  
My Commission Expires May 19, 2007

---

[NOTARIAL SEAL]

STATE OF Georgia §  
COUNTY OF Cobb §  
§

BEFORE ME, the undersigned authority, on this day personally appeared John M. Olsen, Vice President of Bank of America, N.A., known to me to be the person whose name is subscribed to the foregoing instrument, and acknowledged to me that he executed the same for the purposes therein expressed, in the capacity therein stated, and as the act and deed of said corporation.

GIVEN UNDER MY HAND AND SEAL OF OFFICE on this 14<sup>th</sup> day of October, 2005.

Angela R. Parry  
Notary Public Notary Public, Paulding County, Georgia  
My Commission Expires: My Commission Expires June 6, 2009

[NOTARIAL SEAL]

**EXHIBIT A**



Purepac Pharmaceutical Co.

Design (Letter "P" in a Circle)

74336091

Registered

USPD USA TR 0200088

2 Nov 2013

2 Nov 1993

1801834

renewed

Blank Attorney

Class 5  
 Goods Pharmaceutical preparations; namely, adrenals for the treatment of collagen, dermatologic, ophthalmic, respiratory, hematologic, neoplastic, and gastrointestinal diseases and for the treatment of endocrine and rheumatic disorders and allergic states; antibiotics; anticonvulsants; antidepressants; antihistamines; anti-inflammatory agents; antilipemic agents; antithyroid agents; benzodiazepines; cardiac drugs; cephalosporins; combination drugs for the treatment of mild to moderate pain and hypertension; diuretics; hypotensive agents; anxiolytics; sedatives; hypnotics; gastrointestinal drugs; opiate agonists; tetracyclines; tranquilizers and unclassified therapeutic agents for the treatment of gout, myeloproliferative neoplastic disorders and recurrent renal calculi.

Purepac Pharmaceutical Co.

PUREPAC

74277742

Registered

Ostrolenk, Faber, Gerb & Soffen LLP

USPD USA TR 0300293

3 Aug 2013

3 Aug 1993

1785154

See Notes

Blank Attorney

Class 5  
 Goods Pharmaceutical preparations; namely, adrenals for the treatment of collagen, dermatologic, respiratory, hematologic, neoplastic, and gastrointestinal diseases and for the treatment of endocrine and rheumatic disorders and allergic states; antibiotics; anticonvulsants; antidepressants; antihistamines; anti-inflammatory agents; antilipemic agents; antithyroid agents; benzodiazepines; cardiac drugs; cephalosporins; combination drugs for the treatment of mild to moderate pain and hypertension; diuretics; hypotensive agents; anxiolytics; sedatives; hypnotics; gastrointestinal drugs; opiate agonists; tetracyclines; tranquilizers and unclassified therapeutic agents for the treatment of gout, myeloproliferative neoplastic disorders and recurrent renal calculi.

Purepac Pharmaceutical Co.

PUREPAC

78565691

Pending

United States of America

USPD USA O5

11 Feb 2005

Awaiting examination

Fran Politastro

Class 5  
 Goods full line of pharmaceutical preparations and substances